share_log

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $50 Price Target

HC Wainwright & Co.重申买入Halozyme Therapeutics,维持50美元的目标股价
Benzinga ·  05/08 07:30

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $50 price target.

HC Wainwright & Co. 分析师米切尔·卡普尔重申Halozyme Therapeutics(纳斯达克股票代码:HALO)的买入并维持50美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发